pmjТихоокеанский медицинский журналPacific Medical Journal1609-1175TGMU10.34215/1609-1175-2026-2-41-44pmj-3139Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHESСостояние системы матриксных металлопротеиназ у пациентов с внебольничной пневмониейThe status of the matrix metalloproteinase system in patients with community-acquired pneumoniaКнязенкоП. А.KnyazenkoP. A.

Владивосток

Vladivostok

МаркеловаЕ. В.MarkelovaE. V.

Владивосток

Vladivostok

КостюшкоА. В.KostyushkoA. V.

Костюшко Анна Валерьевна – к.м.н., доцент, доцент кафедры нормальной и патологической физиологии.

690002, Владивосток, пр-т Острякова, 2

Anna V. Kostyushko - Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Normal and Pathological Physiology.

2 Ostryakova ave., Vladivostok, 690002

avkostyushko@gmail.comБахтинаЕ. В.BakhtinaE. V.

Владивосток

Vladivostok

ХлыстунЯ. А.KhlystunYa. A.

Владивосток

Vladivostok

Тихоокеанский государственный медицинский университет; Владивостокская клиническая больница № 1РоссияPacific State Medical University; Vladivostok Clinical Hospital No. 1Russian FederationТихоокеанский государственный медицинский университетРоссияPacific State Medical UniversityRussian Federation202619072026024144Copyright © Князенко П.А., Маркелова Е.В., Костюшко А.В., Бахтина Е.В., Хлыстун Я.А., 20262026Князенко П.А., Маркелова Е.В., Костюшко А.В., Бахтина Е.В., Хлыстун Я.А.Knyazenko P.A., Markelova E.V., Kostyushko A.V., Bakhtina E.V., Khlystun Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tmj-vgmu.ru/jour/article/view/3139Цель исследования

Цель исследования: оценить состояние системы матриксных металлопротеиназ (MMP) у пациентов с тяжелым течением внебольничной пневмонии (ВП) по сывороточным уровням MMP-2, MMP-7 и комплексов MMP-9/TIMP-1 и MMP-9/TIMP-2, а также их мониторинг в динамике.

Материалы и методы

Материалы и методы. Проведено открытое наблюдательное сравнительное исследование. В основную когорту включены 55 пациентов с тяжелой ВП. Контрольную группу составили 10 практически здоровых добровольцев. Забор венозной крови на 1, 3, 6, 9, 12-е сутки (в контроле – однократно). Концентрации маркеров определяли методом ИФА. Статистический анализ проводили в пакете SPSS 25.0.

Результаты

Результаты. Динамическое наблюдение показало отсутствие выраженной однонаправленной динамики для MMP-2 и комплексов MMP-9/TIMP, тогда как MMP-7 снижался к 3-м суткам с последующим увеличением, что может соответствовать смене фаз воспалительного повреждения и репарации при гетерогенном течении тяжелой ВП.

Заключение

Заключение. Сывороточный уровень MMP-7 является перспективным маркером тяжести течения ВП, его динамика коррелирует с ранним протеаз-зависимым ремоделированием и усугублением барьерной дисфункции легочной ткани.

Objective

Objective: To assess the status of the matrix metalloproteinase (MMP) system in patients with severe community-acquired pneumonia (CAP) based on serum levels of MMP-2, MMP-7, and the MMP-9/TIMP-1 and MMP-9/TIMP-2 complexes, as well as to monitor these levels over time.

Materials and methods

Materials and methods. An open-label observational comparative study was conducted. The main cohort included 55 patients with severe CAP. The control group consisted of ten normally healthy volunteers. Venous blood samples were collected on days 1, 3, 6, 9, and 12 (in the control group, a single sample was collected). Marker concentrations were determined using the ELISA method. Statistical analysis was performed using SPSS 25.0.

Results

Results. Dynamic monitoring revealed no clear, single-directional dynamics for the MMP-2 and MMP-9/TIMP complexes. However, MMP-7 levels decreased by day 3 and subsequently increased. This may correspond to a shift between the inflammatory and reparative phases during the fluctuating progression of severe CAP.

Conclusion

Conclusion. Serum MMP-7 levels are a promising marker of CAP severity; their dynamics correlate with early protease-dependent remodeling and worsening lung barrier dysfunction.

внебольничная пневмонияматриксные металлопротеиназыбиомаркеры тяжелой пневмонииcommunity-acquired pneumoniamatrix metalloproteinasesbiomarkers of severe pneumoniaавторы заявляют о финансировании проведенного исследования из собственных средствReferencesАндержанова А.А., Мелешкина Ю.А. Внебольничная пневмония: диагностика, подходы к лечению. Клиницист. 2019;13(1–2):55–64. doi 10.17650/1818-8338-2019-13-1-2-55-64Anderzhanova AA, Melyoshkina YuA. Community-acquired pneumonia: diagnosis, treatment approaches. The Clinician. 2019;13(1–2):55–64. (In Russ.). doi 10.17650/1818-8338-2019-13-1-2-55-64Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, van der Poll T. Pneumonia. Nat Rev Dis Primers. 2021;7(1):25. doi: 10.1038/s41572-021-00259-0Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, van der Poll T. Pneumonia. Nat Rev Dis Primers. 2021;7(1):25. doi: 10.1038/s41572-021-00259-0Tsoumani E, Carter JA, Salomonsson S, Stephens JM, Bencina G. Clinical, economic, and humanistic burden of communityacquired pneumonia in Europe: a systematic literature review. Expert Rev Vaccines. 2023;22(1):876–884. doi: 10.1080/14760584.2023.2261785Tsoumani E, Carter JA, Salomonsson S, Stephens JM, Bencina G. Clinical, economic, and humanistic burden of communityacquired pneumonia in Europe: a systematic literature review. Expert Rev Vaccines. 2023;22(1):876–884. doi: 10.1080/14760584.2023.2261785Van Lint P, Libert C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 2006;17(4):217–223. doi: 10.1016/j.cytogfr.2006.04.001Van Lint P, Libert C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 2006;17(4):217–223. doi: 10.1016/j.cytogfr.2006.04.001Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K. Diagnosis and treatment of adults with communityacquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45– e67. doi: 10.1164/rccm.201908-1581STMetlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K. Diagnosis and treatment of adults with communityacquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45– e67. doi: 10.1164/rccm.201908-1581STAghasafari P, George U, Pidaparti R. A review of inflammatory mechanism in airway diseases. Inflamm Res. 2019;68:59–74. doi: 10.1007/s00011-018-1191-2Aghasafari P, George U, Pidaparti R. A review of inflammatory mechanism in airway diseases. Inflamm Res. 2019;68:59–74. doi: 10.1007/s00011-018-1191-2Swenson KE, Swenson ER. Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury. Crit Care Clin. 2021;37(4):749–776. doi: 10.1016/j.ccc.2021.05.003Swenson KE, Swenson ER. Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury. Crit Care Clin. 2021;37(4):749–776. doi: 10.1016/j.ccc.2021.05.003Zhou J, Fang S, Zhu J, Su Y, Zhou H. Multiple Organ Dysfunction Syndrome Associated With Pneumonia: A Retrospective Study With a Focus on Respiratory Failure. Br J Hosp Med. 2025;86(5):1–13.Zhou J, Fang S, Zhu J, Su Y, Zhou H. Multiple Organ Dysfunction Syndrome Associated With Pneumonia: A Retrospective Study With a Focus on Respiratory Failure. Br J Hosp Med. 2025;86(5):1–13.Viasus D, Del Rio-Pertuz G, Simonetti AF, Garcia-Vidal C, Acosta-Reyes J, Garavito A, Carratalà J. Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect. 2016;72(3):273–282. doi: 10.1016/j.jinf.2016.01.002Viasus D, Del Rio-Pertuz G, Simonetti AF, Garcia-Vidal C, Acosta-Reyes J, Garavito A, Carratalà J. Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect. 2016;72(3):273–282. doi: 10.1016/j.jinf.2016.01.002Fan W, Gui B, Zhou X, Li L, Chen H. A narrative review on lung injury: Mechanisms, biomarkers, and monitoring. Crit Care. 2024;28(1):352. doi: 10.1186/s13054-024-05149-xFan W, Gui B, Zhou X, Li L, Chen H. A narrative review on lung injury: Mechanisms, biomarkers, and monitoring. Crit Care. 2024;28(1):352. doi: 10.1186/s13054-024-05149-xNagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3): 562–573. doi: 10.1016/j.cardiores.2005.12.002Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3): 562–573. doi: 10.1016/j.cardiores.2005.12.002Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov. 2014;13:904–927. doi: 10.1038/nrd4390Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov. 2014;13:904–927. doi: 10.1038/nrd4390Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002;37(6):375–536. doi: 10.1080/10409230290771546Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002;37(6):375–536. doi: 10.1080/10409230290771546Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55–71. doi: 10.1016/j.bbamcr.2010.01.003Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55–71. doi: 10.1016/j.bbamcr.2010.01.003

The authors declare that there are no conflicts of interest present.